Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of a Single Dose of E-WE Thrombin, Administered During a Regular Hemodialysis Procedure, in Patients With End-Stage Renal Disease on Chronic Hemodialysis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 01 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
01 Feb 2021 Status changed from recruiting to completed.
06 Nov 2019 Results assessing Safety and Antithrombotic Efficacy of the Recombinant Protein C Activator AB002 in patients with End Stage Renal Disease released at the 61st Annual Meeting and Exposition of the American Society of Hematology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com